Myovant Sciences Liabilities 2025

Myovant Sciences Aktienanalyse

What does Myovant Sciences do?

Myovant Sciences Ltd. is a biotech company based in London that specializes in medications for women and men in various therapy areas. The company was founded in 2016 through the collaboration of Takeda Pharmaceutical and Roivant Sciences Ltd. After going public in 2016, Myovant is now listed on the NYSE. Myovant Sciences focuses on medications for the treatment of reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company is involved in research and development of new therapy options and currently has a pipeline of 5 projects focusing on the following indications: - Symptomatic uterine fibroids - Endometriosis - Prostate cancer - Reproductive disorders in women - Reproductive disorders in men A fibroid is a growth in the tissue of the uterus that often occurs in women of reproductive age and becomes symptomatic. Endometriosis is a chronic, painful condition where tissue that normally lines the uterus grows outside of it. Myovant can also offer treatment options for reproductive disorders in men. The founders of Myovant Sciences aim to improve patient care, especially for rare diseases that are often under-researched and lack effective treatment options. The company focuses on innovative technologies and customized solutions to differentiate themselves from other companies. This includes a focus on targeted therapy options tailored to specific patient groups. Myovant has embraced the motto "Don't become MVP (Most Valuable Player), become MVP - Medical Value Provider." The company works closely with clinics, universities, research institutions, and other companies in the industry to leverage the latest scientific developments and use them for the development of medical solutions for the market. Myovant offers a wide range of products, with a main focus on medications for women and men with severe reproductive system, hormone, and urinary tract disorders in aging individuals. An example of a product is Elagolix, which was developed in collaboration with Abbvie Inc. for the treatment of endometriosis-related pain in women. Myovant Sciences Ltd. is an innovative company with an ambitious goal of developing medications for patients suffering from reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company conducts research and development of products for specific indications in order to offer targeted therapy options for patients. Myovant works closely with numerous partners to develop innovative solutions for patients. Myovant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Myovant Sciences's Liabilities

Myovant Sciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Myovant Sciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Myovant Sciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Myovant Sciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Myovant Sciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Myovant Sciences stock

What is the level of liabilities of Myovant Sciences this year?

Myovant Sciences has a debt balance of 993.49 M USD this year.

What were the liabilities of Myovant Sciences compared to the previous year?

The liabilities of Myovant Sciences have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Myovant Sciences?

High liabilities can pose a risk for investors of Myovant Sciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Myovant Sciences?

Low liabilities mean that Myovant Sciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Myovant Sciences affect the company?

An increase in liabilities of Myovant Sciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Myovant Sciences affect the company?

A decrease in the liabilities of Myovant Sciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Myovant Sciences?

Some factors that can influence the liabilities of Myovant Sciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Myovant Sciences so important for investors?

The liabilities of Myovant Sciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Myovant Sciences take to modify the liabilities?

To change its liabilities, Myovant Sciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Myovant Sciences pay?

Over the past 12 months, Myovant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Myovant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Myovant Sciences?

The current dividend yield of Myovant Sciences is .

When does Myovant Sciences pay dividends?

Myovant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Myovant Sciences?

Myovant Sciences paid dividends every year for the past 0 years.

What is the dividend of Myovant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Myovant Sciences located?

Myovant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Myovant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Myovant Sciences from 6/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2025.

When did Myovant Sciences pay the last dividend?

The last dividend was paid out on 6/1/2025.

What was the dividend of Myovant Sciences in the year 2024?

In the year 2024, Myovant Sciences distributed 0 USD as dividends.

In which currency does Myovant Sciences pay out the dividend?

The dividends of Myovant Sciences are distributed in USD.